Assessment of Circulating Tumor DNA Burden in Patients With Metastatic Gastric Cancer Using Real-World Data
We used RWD to demonstrate that high pretreatment ctDNA burden was associated with worse clinical outcomes in a mGC population receiving 1L chemotherapy-based treatments. Our analysis suggests ctDNA burden could be used as a prognostic biomarker for mGC.
Authors
- Carol E. Peña (ORCID: https://orcid.org/0000-0002-8712-5396)
- Angela Watkins
- Carin R. Espenschied (ORCID: https://orcid.org/0000-0001-6108-7785)
- Senaka Peter (ORCID: https://orcid.org/0000-0002-1081-8936)
- Jiemin Liao (ORCID: https://orcid.org/0000-0001-6848-5532)
- Răzvan Cristescu (ORCID: https://orcid.org/0000-0002-9978-0339)
- Nicole Zhang (ORCID: https://orcid.org/0009-0001-2706-5838)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Guardant (United States) (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1200/po-24-00582
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94